Cargando…

Central serous chorioretinopathy secondary to intramuscular testosterone therapy

SUMMARY: A patient treated with intramuscular testosterone replacement therapy for primary hypogonadism developed blurred vision shortly after receiving his testosterone injection. The symptom resolved over subsequent weeks and recurred after his next injection. A diagnosis of central serous chorior...

Descripción completa

Detalles Bibliográficos
Autores principales: Lockhart, M, Ali, E, Mustafa, M, Tormey, W, Sreenan, S, Saaed, A, McDermott, JH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337839/
https://www.ncbi.nlm.nih.gov/pubmed/37212480
http://dx.doi.org/10.1530/EDM-22-0348
_version_ 1785071502104723456
author Lockhart, M
Ali, E
Mustafa, M
Tormey, W
Sreenan, S
Saaed, A
McDermott, JH
author_facet Lockhart, M
Ali, E
Mustafa, M
Tormey, W
Sreenan, S
Saaed, A
McDermott, JH
author_sort Lockhart, M
collection PubMed
description SUMMARY: A patient treated with intramuscular testosterone replacement therapy for primary hypogonadism developed blurred vision shortly after receiving his testosterone injection. The symptom resolved over subsequent weeks and recurred after his next injection. A diagnosis of central serous chorioretinopathy (CSR) was confirmed following ophthalmology review. A decision was made to change the patient’s testosterone regime from this 12-weekly intramuscular injection to a daily topical testosterone gel, given the possibility that peak blood levels of testosterone following intramuscular injection were causing his ocular complaint. His CSR did not recur after this change in treatment. CSR secondary to testosterone therapy is a rare finding but has been reported previously in the literature. LEARNING POINTS: Blurred vision in patients treated with testosterone replacement therapy (TRT) should prompt an ophthalmology review. The potential for reduced risk of central serous chorioretinopathy (CSR) with daily transdermal testosterone remains a matter of conjecture. CSR is a rare potential side effect of TRT.
format Online
Article
Text
id pubmed-10337839
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-103378392023-07-13 Central serous chorioretinopathy secondary to intramuscular testosterone therapy Lockhart, M Ali, E Mustafa, M Tormey, W Sreenan, S Saaed, A McDermott, JH Endocrinol Diabetes Metab Case Rep Unusual Effects of Medical Treatment SUMMARY: A patient treated with intramuscular testosterone replacement therapy for primary hypogonadism developed blurred vision shortly after receiving his testosterone injection. The symptom resolved over subsequent weeks and recurred after his next injection. A diagnosis of central serous chorioretinopathy (CSR) was confirmed following ophthalmology review. A decision was made to change the patient’s testosterone regime from this 12-weekly intramuscular injection to a daily topical testosterone gel, given the possibility that peak blood levels of testosterone following intramuscular injection were causing his ocular complaint. His CSR did not recur after this change in treatment. CSR secondary to testosterone therapy is a rare finding but has been reported previously in the literature. LEARNING POINTS: Blurred vision in patients treated with testosterone replacement therapy (TRT) should prompt an ophthalmology review. The potential for reduced risk of central serous chorioretinopathy (CSR) with daily transdermal testosterone remains a matter of conjecture. CSR is a rare potential side effect of TRT. Bioscientifica Ltd 2023-05-02 /pmc/articles/PMC10337839/ /pubmed/37212480 http://dx.doi.org/10.1530/EDM-22-0348 Text en © the author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Unusual Effects of Medical Treatment
Lockhart, M
Ali, E
Mustafa, M
Tormey, W
Sreenan, S
Saaed, A
McDermott, JH
Central serous chorioretinopathy secondary to intramuscular testosterone therapy
title Central serous chorioretinopathy secondary to intramuscular testosterone therapy
title_full Central serous chorioretinopathy secondary to intramuscular testosterone therapy
title_fullStr Central serous chorioretinopathy secondary to intramuscular testosterone therapy
title_full_unstemmed Central serous chorioretinopathy secondary to intramuscular testosterone therapy
title_short Central serous chorioretinopathy secondary to intramuscular testosterone therapy
title_sort central serous chorioretinopathy secondary to intramuscular testosterone therapy
topic Unusual Effects of Medical Treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337839/
https://www.ncbi.nlm.nih.gov/pubmed/37212480
http://dx.doi.org/10.1530/EDM-22-0348
work_keys_str_mv AT lockhartm centralserouschorioretinopathysecondarytointramusculartestosteronetherapy
AT alie centralserouschorioretinopathysecondarytointramusculartestosteronetherapy
AT mustafam centralserouschorioretinopathysecondarytointramusculartestosteronetherapy
AT tormeyw centralserouschorioretinopathysecondarytointramusculartestosteronetherapy
AT sreenans centralserouschorioretinopathysecondarytointramusculartestosteronetherapy
AT saaeda centralserouschorioretinopathysecondarytointramusculartestosteronetherapy
AT mcdermottjh centralserouschorioretinopathysecondarytointramusculartestosteronetherapy